DailyMed: Zepbound prescribing information
Source of approved indication scope for tirzepatide under this brand context.
Evidence memo
Tirzepatide
Also tracked as: Zepbound, Mounjaro
An approved incretin-pathway medicine with strong obesity and diabetes evidence and expanding indication-specific use.
Post-market evidence Approved specific use
Evidence status
Clinically established in specific contexts. Evidence level: Post-market evidence.
Claim being evaluated
Which outcomes are supported by labeled indications and pivotal trials, and where broader wellness claims are overstated.
Why people care
Tirzepatide is one of the clearest examples of a metabolic therapy moving from glucose control into obesity and obesity-related disease outcomes.
Signal so far
Approved uses and major clinical programs support strong effects in specific metabolic contexts.
Biggest unknown
Long-term real-world outcomes, discontinuation, tolerability, access, and claims beyond studied populations.
Safety/regulatory boundary
Product identity matters. Label-based evidence should not be generalized to unverified compounded or internet-market products.
Watch next
Post-market safety, outcomes studies, comparative effectiveness, and indication expansions.
Evidence interpretation
Clinically established in defined contexts; still not a general-purpose wellness shortcut.